Big pharma
The largest drugmakers, selling prescription medicines worldwide.
Raggruppate con l’aiuto di un modello di IA e riviste dalla nostra redazione. La riga sotto ogni azienda spiega perché è qui.
I prezzi delle azioni sono quelli di chiusura del 11 nov 2026, dal feed della borsa IEX.
Grade mix
A 7B 3C 3
Revenue growing
12 of 12
Free cash flow growing
9 of 13
Median price move, 1 year
+34,0%
- LLYELI LILLY AND COMPANY
Drug manufacturers generalMarket cap 1,35T USDP/E 46,67
1437,79 USD+42,2%1YSince added +23,2%
A+- Crescita e cassa
- Cresce con forza
- Business trend
- Stabile
- Business quality
- Forte
- Getting better
- In miglioramento
Revenue
86,5B USD+45,5%Profit
27,6B USD+49,8%Free cash flow
19,7B USD+112,1%Why it is here: Sells prescription medicines for diabetes, obesity, cancer and inflammation
- JNJJohnson & Johnson
Drug manufacturers generalMarket cap 674,9B USDP/E 42,54
280,34 USD+47,5%1YSince added +12,8%
A+- Crescita e cassa
- Cresce con forza
- Business trend
- Stabile
- Business quality
- Forte
- Getting better
- Misto
Revenue
99,3B USD+7,8%Profit
16,1B USD-35,9%Free cash flow
20,6B USD+5,1%Why it is here: Sells prescription medicines for cancer and immune disorders
- ABBVAbbVie Inc.
Drug manufacturers generalMarket cap 521,2B USDP/E 50,75
294,87 USD+30,2%1YSince added +7,5%
B+- Crescita e cassa
- Cresce con forza
- Business trend
- Stabile
- Business quality
- Forte
- Getting better
- In miglioramento
Revenue
66B USD+10,7%Profit
10,3B USD+333,1%Free cash flow
18,9B USD-4,1%Why it is here: Sells medicines for immune, neurological and cancer conditions
- MRKMerck & Co., Inc.
Drug manufacturers generalMarket cap 362,9B USDP/E 150,20
147,20 USD+65,7%1YSince added +3,7%
A- Crescita e cassa
- Cresce con forza
- Business trend
- Stabile
- Business quality
- Solida
- Getting better
- Misto
Revenue
67,4B USD+4,9%Profit
2,5B USD-87,1%Free cash flow
14,7B USD+13,0%Why it is here: Sells prescription medicines and vaccines for people and animals
- NVSNovartis AG
Drug manufacturers generalMarket cap 306B USDNessun P/E (perdita operativa)
160,36 USD+23,6%1YSince added +12,6%
A- Crescita e cassa
- Cresce con forza
- Business quality
- Mista
- Getting better
- Migliora nettamente
Revenue
56,7B USD+9,6%Profit
-46M USDNo comparable yearFree cash flow
17,6B USD+8,3%Why it is here: Sells prescription medicines
- AZNASTRAZENECA PLC
Drug manufacturers generalMarket cap 289,7B USDP/E 28,36
185,49 USD+115,2%1YSince added +19,0%
B+- Crescita e cassa
- Cresce con forza
- Business trend
- In rallentamento
- Business quality
- Forte
- Getting better
- Migliora nettamente
Revenue
62,4B USD+7,3%Profit
10,2B USD+45,3%Free cash flow
11,8B USD+18,4%Why it is here: Sells prescription medicines
- NVONOVO NORDISK A/S
Drug manufacturers generalMarket cap 182,8B USDP/E 11,84
41,10 USD-15,4%1YSince added +8,0%
C+- Crescita e cassa
- In crescita
- Business trend
- In accelerazione
- Business quality
- Forte
- Getting better
- In miglioramento
Revenue
50,3B USD+5,7%Profit
17,1B USD+9,1%Free cash flow
8,9B USD-20,1%Why it is here: Sells diabetes and obesity medicines
- PFEPFIZER INC
Drug manufacturers generalMarket cap 167,9B USDP/E 42,07
29,45 USD+21,4%1YSince added +3,8%
C- Crescita e cassa
- Cresce con forza
- Business trend
- In contrazione
- Business quality
- Solida
- Getting better
- Misto
Revenue
63,6B USD+1,3%Profit
4B USD-59,0%Free cash flow
11,8B USD+13,6%Why it is here: Sells prescription medicines and vaccines
- BMYBRISTOL-MYERS SQUIBB COMPANY
Drug manufacturers generalMarket cap 128,6B USDP/E 13,95
62,92 USD+34,0%1YSince added +11,0%
C+- Crescita e cassa
- In crescita
- Business trend
- Stabile
- Business quality
- Forte
- Getting better
- Migliora nettamente
Revenue
50B USD+4,2%Profit
9,2B USD+53,1%Free cash flow
9,3B USD-39,3%Why it is here: Sells prescription medicines for cancer and immune conditions
- SNYSanofi
Drug manufacturers generalMarket cap 59,1B USDP/E 6,81
48,43 USD-3,0%1YSince added +23,9%
B- Crescita e cassa
- Cresce con forza
- Business trend
- Stabile
- Business quality
- Mista
- Getting better
- In miglioramento
Revenue
53,5B USD+11,6%Profit
4,7B USD-54,2%Free cash flow
8,1B USD+22,5%Why it is here: Sells prescription medicines and vaccines
- GSKGSK plc
Drug manufacturers generalMarket cap 109,2B USDP/E 13,60
50,60 USD+8,9%1YSince added +9,3%
A+- Crescita e cassa
- Cresce con forza
- Business quality
- Forte
- Getting better
- Migliora nettamente
Revenue
43,8B USD+4,1%Profit
7,7B USD+122,0%Free cash flow
8,6B USD+24,0%Why it is here: Sells prescription medicines and vaccines worldwide
- AMGNAmgen Inc.
Drug manufacturers generalMarket cap 253,2B USDP/E 27,14
468,13 USD+43,1%1YSince added +13,4%
A+- Crescita e cassa
- Cresce con forza
- Business trend
- Stabile
- Business quality
- Forte
- Getting better
- In miglioramento
Revenue
38,9B USD+8,2%Profit
9,4B USD+34,1%Free cash flow
9,6B USD-17,0%Why it is here: Develops and sells medicines and biosimilars for serious diseases
- TAKTakeda Pharmaceutical Company Limited
Drug manufacturers specialty and genericMarket cap 33,5B USDP/E 48,79
20,86 USD+50,1%1YSince added +12,5%
A- Crescita e cassa
- Cresce con forza
- Business quality
- Mista
- Getting better
- Misto
Revenue
29,8B USDNo comparable yearProfit
259,4M USDNo comparable yearFree cash flow
5,5B USD+1,1%Why it is here: Sells prescription medicines and vaccines globally
Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.
Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.
DiscussionNo comments yet
Be civil and stick to the companies. Comments are opinions, not advice.